Effects of defibrotide on fibrinolytic activity in diabetic patients with stable angina pectoris

Davı̀, Giovanni; Catalano, Isabella; Belvedere, Mario; Amato, Salvatore; Mogavero, A.; Giammarresi, Carlo; Alaimo, P.; Notarbartoló, A

doi:10.1016/0049-3848(92)90241-2

Cited by 5 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[26][27][28][29] Our data show that DF utilized at any dose does not influence the levels of PAI-1; however, it prevents the upregulation of PAI-1 induced by LPS. We hypothesize that DF interferes with the mechanisms by which the proinflammatory stimulus LPS induces PAI-1 synthesis.…”

Section: Discussionmentioning

confidence: 99%

Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells

et al. 2003

View full text Add to dashboard Cite

Defibrotide (DF), a polydeoxyribonucleotide with antithrombotic properties, has recently proven effective in patients with severe hepatic veno-occlusive disease (VOD), a life-threatening complication of high-dose chemo/radiotherapy regimens for stem cell transplantation. To understand the mechanism of its beneficial effect, we studied the impact of DF on the expression of tissue factor (TF) and fibrinolytic proteins (PAI-1 and t-PA) on endothelial cells. The in vitro response to DF of two types of human endothelial cells (ECs) of different origins, that is from macrovascular (HUVEC) and microvascular (HMEC-1 cell line) beds, was evaluated in the presence or absence of a proinflammatory stimulus (ie bacterial endotoxin, LPS). The results show that DF was able to significantly reduce the LPSinduced TF expression by HMEC-1, and less prominently by HUVEC. In addition, DF importantly influenced the fibrinolytic properties of both HMEC-1 and HUVEC. Specifically, it dosedependently counteracted the LPS-induced increase in PAI-1 levels and decrease in t-PA activity expression. It also significantly incremented t-PA antigen in resting EC. Decreasing the procoagulant activity and increasing the fibrinolytic potential of EC favors an anticoagulant phenotype of the endothelium, which may protect from fibrin deposition and vascular occlusion.

show abstract

Section: Discussionmentioning

confidence: 99%

Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells

et al. 2003

View full text Add to dashboard Cite

show abstract

“…В настоящее время получены обнадеживающие результаты исследований о лечении ТА-ТМА с использованием дефибротида [15,16]. На животных моделях и исследованиях на людях было показано, что этот препарат влияет на агрегацию тромбоцитов [17] и уровень в плазме ряда белков с антитромботической активностью, включая t-PA и PAI-1, простациклин, тромбомодулин [18,19], тем самым снижая прокоагулянтную активность [20]. Кроме того, дефибротид защищает эндотелий от повреждающего воздействия ингибиторов кальциневрина и сиролимуса [21].…”

Section: профилактика и лечение трансплантационно-ассоциированной тромботической микроангиопатииunclassified

Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice

Мачнева

Болохонова

Алиев

et al. 2020

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Associated hematopoietic stem cell transplantation (HSCT) or transplant-associated thrombotic microangiopathy (TA-TMA) is currently a generally recognized and severe complication of HSCT with a high risk of mortality. TMA is characterized by microangiopathic hemolytic anemia and thrombocytopenia, resulting in the accumulation of platelets in the microvasculature, which leads to dysfunction of the ischemic organ. The pathogenesis of TА-TMA is based on endothelial damage by various trigger factors (in particular, chemotherapeutic agents in the conditioning regimen, the use of calcineurin inhibitors, alloreactivity, infectious agents). The article presents the peculiarities of terminology, pathogenesis and clinical manifestations of TA-TMA, methods of therapy for this pathology. Examples of management of patients with TA-TMA are demonstrated using a clinical example.

show abstract

Defibrotide: a review on clinical use and future development

Larocca

Cavallo

Magarotto

et al. 2008

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Effects of defibrotide on fibrinolytic activity in diabetic patients with stable angina pectoris

Cited by 5 publications

References 14 publications

Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells

Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells

Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice

Defibrotide: a review on clinical use and future development

Contact Info

Product

Resources

About